Moreover, PTPN2‐deficient CAR T cells were effective in repressing tumour growth even without the co‐administration of IL‐2 (Fig 4G) that is used routinely in rodent pre‐clinical models to promote CAR T‐cell expansion but is not used in the clinic. The gene discussed is IL2; the disease is neoplasm.